Brachytherapy for Prostate Cancer: Procedure, Benefits, Risks and Cost

Brachytherapy is an established form of radiation treatment for prostate cancer. This guide sits beside the Radiation Therapy for Prostate Cancer article, the Prostate Cancer Treatment in India pathway, treatment without surgery and Robotic Prostatectomy in India.

Instead of sending radiation toward the prostate from a machine outside the body, brachytherapy places the radiation source inside the prostate or very close to it.

This allows a high radiation dose to be concentrated around the prostate while limiting radiation exposure to surrounding tissues.

The prostate is located close to the bladder, rectum and other important structures.

Because the radioactive source is placed close to the treatment target, brachytherapy can create a steep dose fall-off outside the prostate.

In simple terms:

The radiation is delivered where it is needed rather than travelling through the body from a distant machine.

The American Cancer Society describes brachytherapy as internal radiation therapy in which radioactive material is placed directly inside the prostate.

International patients comparing radiation oncologists commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

Brachytherapy uses a carefully planned radiation dose to damage the DNA of prostate cancer cells.

Cancer cells are less able to repair this damage than normal cells.

The radiation source is positioned using imaging and specialised treatment-planning software.

The radiation oncologist determines:

The objective is to treat the prostate effectively while limiting unnecessary radiation to the bladder, rectum, urethra and surrounding tissues.

There are two principal forms.

Also called LDR brachytherapy or permanent seed brachytherapy.

Tiny radioactive seeds are inserted into the prostate.

The seeds remain there and release radiation gradually over a period of months.

The seeds are approximately the size of grains of rice.

Common radioactive materials include:

The choice depends on the treatment centre and clinical protocol.

The American Cancer Society explains that LDR seeds remain in the prostate and deliver low-dose radiation over weeks or months.

Also called HDR brachytherapy or temporary brachytherapy.

Instead of leaving radioactive seeds inside the prostate, the treatment uses temporary tubes or catheters.

A radioactive source travels through these tubes and remains in position for a short period, usually minutes at a time.

The source is then removed.

Nothing radioactive remains inside the prostate after the HDR treatment is completed.

This is one of the major differences between HDR and LDR brachytherapy.

Prostate Cancer UK describes HDR brachytherapy as a temporary treatment in which a radioactive source is passed through thin tubes into the prostate and then removed.

The exact protocol varies between hospitals and patients. See brachytherapy cost in India for the GAF planning range.

Brachytherapy is not suitable for every prostate cancer patient.

The radiation oncology team considers several factors.

These include:

Brachytherapy is particularly relevant for selected localized prostate cancers.

The EAU patient guidance identifies radiotherapy, including brachytherapy, as an established treatment option for localized prostate cancer.

Yes.

For selected low-risk localized prostate cancers, LDR brachytherapy can be used as a definitive treatment.

However, active surveillance may also be appropriate for some low-risk patients.

Therefore, the decision is not simply:

“Can brachytherapy treat the cancer?”

It is:

“Does definitive brachytherapy provide enough benefit to justify treatment in this particular patient?”

Prostate Cancer UK notes that permanent seed brachytherapy can be used for localized low-risk prostate cancer and may provide cancer-control outcomes comparable with other established definitive treatments.

Brachytherapy has an important role in selected intermediate-risk prostate cancers.

The treatment depends on whether the disease is:

Some patients may receive brachytherapy alone while others may receive external beam radiation + brachytherapy.

Hormone therapy may also be added depending on the risk profile.

The treatment should therefore be planned according to the specific risk category rather than simply the word “intermediate.”

High-risk prostate cancer generally requires more intensive treatment.

Brachytherapy may be used as a boost alongside external beam radiation.

For example:

External beam radiation + HDR brachytherapy + hormone therapy

may be considered for selected patients.

The reason for combining treatments is that external beam radiation can treat a broader area while brachytherapy delivers an additional concentrated dose to the prostate.

Prostate Cancer UK describes HDR brachytherapy as a possible boost when combined with external beam radiation for localized or locally advanced prostate cancer.

Locally advanced prostate cancer has extended outside the prostate but has not necessarily spread to distant organs.

Brachytherapy may be incorporated into a combination treatment plan in selected patients.

A typical treatment pathway may include:

The exact combination depends on extent of local disease, Grade Group, PSA, imaging, lymph-node involvement and patient health.

Not every locally advanced patient is suitable for brachytherapy.

Brachytherapy is not generally the main treatment for widespread metastatic prostate cancer.

When prostate cancer has spread to distant organs, systemic treatments such as hormone therapy and other medicines usually play the central role.

Radiation may still be used for selected areas of disease, particularly for symptom control.

Brachytherapy is primarily a treatment directed at the prostate rather than a whole-body treatment.

Permanent seed brachytherapy is the classic LDR approach.

Small radioactive seeds are inserted directly into the prostate.

The seeds stay there permanently.

They release most of their radiation during the early months after implantation.

The radioactivity then gradually decreases.

Prostate Cancer UK notes that the seeds deliver radiation over several months, with most of the radiation released during the first few months and very little remaining after roughly 8–10 months.

The seeds do not normally need to be removed.

The procedure usually involves several stages.

The patient receives anaesthesia, commonly general or spinal anaesthesia depending on the centre and clinical circumstances.

A transrectal ultrasound probe is used to visualise the prostate.

This allows the team to see the prostate during the implantation procedure.

The prostate is mapped using imaging.

Specialised software calculates where the radioactive seeds should be placed.

The goal is to cover the prostate adequately while limiting radiation to nearby structures.

Thin needles are passed through the perineum.

The perineum is the area between the scrotum and anus.

The needles are guided into predetermined positions.

Radioactive seeds are deposited through the needles.

The number of seeds depends on prostate size, treatment plan, prescribed radiation dose and seed type.

Once the seeds have been placed, the needles are removed.

The radioactive seeds remain inside the prostate.

HDR brachytherapy uses a temporary radioactive source.

Thin tubes are inserted into the prostate through the perineum.

The radiation source is then passed through the tubes.

It remains in position for a predetermined amount of time.

The source is subsequently withdrawn.

The catheters may then be removed, depending on the treatment protocol.

Prostate Cancer UK describes the HDR procedure as involving approximately 10–20 tubes in many treatment settings, followed by temporary insertion of the radioactive source.

The patient is given instructions about fasting, bowel preparation, medicines, blood thinners and other medical conditions.

General or spinal anaesthesia may be used.

The patient generally does not feel the catheter-placement procedure while under anaesthesia.

An ultrasound probe is inserted through the rectum.

This provides an image of the prostate.

Thin hollow tubes are placed through the perineum and into the prostate.

The position of each catheter is carefully checked.

CT, MRI or ultrasound imaging may be used to calculate the exact radiation dose.

The treatment-planning system determines how long the radioactive source should remain in each catheter.

The radioactive source travels through the catheters.

It stays at predetermined positions for specific periods.

The source is then removed.

After treatment, the catheters are removed according to the centre's protocol.

Because the radioactive source is removed, there is no permanent radioactive material left inside the prostate.

The overall time depends on whether the patient receives LDR or HDR treatment.

LDR usually involves a single implantation procedure.

HDR may involve one or several treatment sessions depending on the treatment plan.

The actual radiation delivery can be brief, but the complete procedure also includes anaesthesia, imaging, catheter or needle placement, treatment planning and recovery.

Some patients go home the same day.

Others stay overnight.

HDR brachytherapy may require a one- or two-day hospital stay depending on the treatment protocol.

Prostate Cancer UK states that many men undergoing HDR brachytherapy stay in hospital for one or two days and may return to normal activities within about a week.

The GAF planning sheet for brachytherapy uses a typical 1–7 night range because some combination protocols and recovery needs take longer.

The exact stay depends on type of brachytherapy, number of treatments, anaesthesia, urinary function, hospital protocol and recovery.

The procedure itself is usually performed under anaesthesia.

Therefore, the implantation procedure should not be painful while it is being performed.

Afterwards, some patients may experience:

These symptoms are usually temporary but can vary in severity.

The radiation team needs to determine whether the prostate can be safely and accurately treated.

Evaluation may include:

The prostate's size and shape are particularly relevant for brachytherapy planning.

A very large prostate can make seed placement more difficult.

It may also increase the risk of urinary problems after treatment.

In selected patients, hormone therapy may be given before brachytherapy to shrink the prostate.

The American Cancer Society notes that a large prostate can make seed placement more difficult and that hormone therapy may sometimes be used beforehand to reduce prostate size.

This requires careful assessment.

Patients with significant urinary obstruction may have a higher risk of urinary complications after brachytherapy.

Symptoms that should be discussed include:

Brachytherapy may still be possible in some patients, but the urinary function needs to be evaluated first.

A previous transurethral resection of the prostate (TURP) does not automatically rule out brachytherapy.

However, it can affect eligibility and complication risk.

The timing of the TURP, size and location of the resection cavity and current urinary function may all matter.

The American Cancer Society notes that men who have previously undergone TURP or have significant urinary problems may have a higher risk of urinary side effects from brachytherapy.

Patients should provide the radiation oncologist with details of previous prostate procedures.

Hormone therapy may be used before, during or after brachytherapy.

It can have several purposes.

For a large prostate, hormone therapy may reduce its size before implantation.

Hormone therapy may be combined with radiation for higher-risk prostate cancer.

Systemic hormone treatment can address cancer cells outside the prostate that local radiation cannot reach.

The duration depends on the cancer risk group and treatment plan.

Brachytherapy alone can be appropriate for selected localized prostate cancers.

It is most commonly considered when:

The American Cancer Society states that brachytherapy alone is generally used for selected early-stage, lower-risk prostate cancers.

For higher-risk disease, brachytherapy may be combined with external beam radiation.

This is sometimes called a brachytherapy boost.

The logic is straightforward:

External beam radiation treats a broader area, while brachytherapy delivers an additional high dose directly to the prostate.

This can be useful when the cancer has a higher risk of recurrence.

The trade-off is that combination treatment can also increase treatment burden and side effects.

A combination plan may look like:

External beam radiation + HDR brachytherapy + hormone therapy

This is not necessary for every patient.

It is considered mainly for selected intermediate- to high-risk or locally advanced disease.

The exact sequence can vary.

Some patients receive external radiation before HDR brachytherapy.

Others receive brachytherapy first.

The radioactive source is positioned directly in the prostate.

This allows high radiation doses to be delivered to the target.

LDR generally involves one implantation.

HDR may involve a small number of treatment sessions.

This can be much shorter than some conventional external radiation schedules.

Brachytherapy does not require removal of the prostate.

The procedure uses needles or catheters inserted through the perineum.

Many patients do not require prolonged hospitalisation.

For selected higher-risk cancers, brachytherapy can provide a focused radiation boost.

For patients who prefer a non-surgical definitive treatment, brachytherapy can be an important option when clinically appropriate.

Brachytherapy is not appropriate for everyone.

Potential limitations include:

Patient selection is therefore critical.

Side effects depend on the technique and individual patient.

The main categories are urinary, bowel, sexual and procedure-related.

Urinary symptoms are among the most common side effects.

Patients may experience:

The American Cancer Society notes that urinary irritation and frequency can occur because the urethra is close to the treated prostate.

Some patients can temporarily have difficulty passing urine after treatment.

The risk may be higher in patients who already have poor urinary flow, a large prostate or significant urinary symptoms.

In some cases, a urinary catheter may be required temporarily.

This is one reason urinary function should be assessed before treatment.

The rectum lies immediately behind the prostate.

Some radiation can therefore reach the rectum.

Possible symptoms include:

Serious long-term bowel complications are uncommon, but they can occur.

The American Cancer Society identifies radiation proctitis and bowel symptoms as possible complications of prostate brachytherapy.

Brachytherapy can affect erections.

However, erectile dysfunction may develop gradually rather than immediately.

The risk depends on age, erectile function before treatment, other health conditions, radiation dose, hormone therapy and baseline cardiovascular health.

A patient should discuss sexual function before treatment.

Brachytherapy does not remove the prostate.

Therefore, ejaculation may remain possible.

However, radiation can affect erectile function, ejaculatory volume, sexual desire and semen production.

Hormone therapy, when combined with brachytherapy, can also significantly reduce libido and erectile function while treatment is active.

Radiation to the prostate can affect fertility.

Men who may want biological children should discuss fertility preservation before treatment.

Depending on the patient's age and circumstances, sperm banking may be considered.

This discussion is best held before radiation begins.

Rare complications may include:

Apollo Hospitals lists urinary difficulty, rectal bleeding and urethral narrowing among potential complications, while serious complications such as fistula are rare.

One important difference between LDR and HDR treatment is radiation safety after treatment.

With LDR, radioactive seeds remain inside the prostate.

The radiation emitted outside the body is low, but the medical team may provide temporary precautions.

These may include limiting close contact with pregnant women and small children.

The exact precautions depend on the radioactive isotope and hospital protocol.

The American Cancer Society also notes that patients receiving permanent seed brachytherapy may receive temporary radiation-safety instructions and should carry treatment documentation when travelling because airport detection systems can sometimes detect low radiation levels.

No radioactive source remains in the body after HDR treatment.

The radioactive source is removed at the end of each treatment.

Therefore, once the treatment is complete and the source has been removed, patients do not continue emitting radiation from the treatment source.

Prostate Cancer UK specifically notes that no radioactive material is left in the prostate following temporary HDR treatment.

Travel timing depends on the treatment type.

Because the radioactive source is removed, there are generally no ongoing radiation precautions related to the source.

However, the patient may still need time to recover from anaesthesia, catheter placement, perineal soreness and urinary symptoms.

The seeds remain inside the prostate.

Patients may therefore receive temporary radiation-safety instructions.

International travellers should carry a treatment letter because security systems at airports can sometimes detect implanted radioactive material.

Recovery is usually shorter than recovery from major prostate surgery.

However, urinary symptoms can last longer than the immediate recovery period.

Possible symptoms include perineal soreness, bruising, blood in urine, burning while urinating and urinary frequency.

Urinary symptoms may continue. Some patients experience urgency, weak flow, nighttime urination and bowel changes. Symptoms often improve gradually.

Urinary function generally settles progressively.

Sexual function may take longer to change and recover.

PSA is monitored over time to evaluate the treatment response.

Recovery depends on the treatment technique.

After HDR brachytherapy, Prostate Cancer UK notes that many patients can return to normal activities within approximately a week.

LDR recovery can also be relatively quick physically, although urinary symptoms may continue for several weeks or longer.

Heavy lifting and strenuous exercise should be resumed according to the treating team's instructions.

The prostate remains in the body after brachytherapy.

Therefore, PSA does not immediately fall to zero as it can after radical prostatectomy.

Instead, PSA generally declines gradually.

It can take months or longer to reach its lowest level.

A temporary PSA increase can also occur.

This is sometimes called a PSA bounce.

A single PSA increase does not automatically mean the cancer has returned.

The doctor evaluates the PSA pattern over time.

A PSA bounce is a temporary increase in PSA followed by a subsequent decline.

It is particularly recognised after radiation-based treatments such as brachytherapy.

This can cause unnecessary anxiety if the patient assumes that every PSA increase represents recurrence.

Doctors therefore interpret PSA using previous PSA levels, time since treatment, PSA trend, symptoms, treatment type and imaging when indicated.

The main follow-up tool is PSA.

Doctors may also use clinical assessment, MRI, PSMA PET/CT and other imaging when there is a specific concern.

The PSA nadir and subsequent trend are important.

The exact definition of biochemical recurrence after radiation differs from recurrence after prostatectomy.

Patients should therefore not compare their PSA directly with someone who has had surgery.

Treatment depends on where the cancer has returned.

Possibilities can include:

The previous radiation dose is an important factor when planning further treatment.

The two approaches can also be used together. See Radiation Therapy for Prostate Cancer for IMRT, IGRT, VMAT and SBRT.

These treatments are fundamentally different.

Neither treatment is automatically right for every patient. See Robotic Prostatectomy in India.

Active surveillance and brachytherapy have different goals.

No immediate definitive treatment. The cancer is monitored.

The cancer is actively treated with radiation.

Active surveillance may be suitable for selected low-risk patients who want to avoid immediate treatment. See treatment without surgery.

Brachytherapy may be appropriate for patients who want definitive treatment and meet the selection criteria.

Brachytherapy is available at specialised cancer centres in India.

Depending on the centre, patients may have access to:

Availability varies between hospitals.

Patients should confirm whether the centre performs prostate-specific brachytherapy and whether it offers LDR, HDR or both. Compare radiation hospitals in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

The cost depends on the treatment technique and hospital.

Apollo Hospitals currently publishes an indicative brachytherapy cost of approximately ₹1 lakh to ₹2.5 lakh.

This is a general brachytherapy estimate and should not be interpreted as a fixed price for every prostate cancer patient.

GAF Healthcare's published planning range for brachytherapy in India is $5,500–$13,000, typically with a 1–7 night stay depending on the technique.

Prostate-specific costs can vary because of LDR vs HDR, radioactive isotope, number of treatment sessions, treatment planning, anaesthesia, hospitalisation, imaging, urologist and radiation-oncologist fees, additional external beam radiation and hormone therapy.

City pages use the same national planning ranges unless a hospital issues a verified quotation: Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

Before accepting a quotation, ask whether it includes:

Different hospitals package these services differently.

There is no universal price difference.

LDR involves radioactive seeds, implantation, treatment planning and seed placement.

HDR involves catheter placement, anaesthesia, treatment planning, a temporary radioactive source and one or more treatment sessions.

If HDR is combined with external beam radiation and hormone therapy, the total treatment cost can be significantly higher than brachytherapy alone.

For a patient travelling to India, the hospital bill is only one component.

The overall budget may include medical costs (consultation, imaging, biopsy review, brachytherapy, external radiation, hormone therapy, medicines, follow-up), travel (flights, airport transfers, local transportation), accommodation for the entire schedule, and attendant expenses.

The length of stay depends on whether the patient is receiving brachytherapy alone, HDR + EBRT, or EBRT + hormone therapy.

Send the hospital or medical coordinator:

The specialist team can then determine whether brachytherapy is likely to be appropriate.

A preliminary estimate can then be prepared.

The final treatment plan may change after physical examination or additional imaging.

The answer depends on the treatment pathway.

The medical stay may be relatively short.

The patient may need to remain in India for the complete external radiation schedule.

Hormone therapy may continue after the patient returns home.

The treating hospital should provide a clear timeline covering arrival, consultation, tests, treatment, recovery, follow-up and return travel.

Ask the hospital:

Fact: This applies to LDR permanent seeds, not HDR. HDR uses a radioactive source that is removed after treatment.

Fact: Age alone does not determine eligibility. Cancer risk, anatomy, urinary function and overall health are more relevant.

Fact: Prostate brachytherapy is an established radiation treatment used for selected localized prostate cancers.

Fact: Patient selection is important. Prostate size, urinary symptoms, cancer risk and disease extent all matter.

Fact: Urinary, bowel and sexual side effects can occur even with highly targeted treatment.

Fact: Both are brachytherapy, but the radiation delivery method is different.

Fact: Brachytherapy itself is generally a short-stay procedure. The overall stay becomes longer when it is combined with a course of external radiation.

Brachytherapy is internal radiation therapy in which radioactive material is placed inside or near the prostate to deliver radiation directly to the treatment area.

It is an invasive radiation procedure rather than a prostate-removal operation. Needles or catheters are inserted through the perineum under imaging guidance.

The two main types are LDR permanent seed brachytherapy and HDR temporary brachytherapy.

LDR brachytherapy permanently places tiny radioactive seeds inside the prostate. The seeds release radiation gradually over several months.

HDR brachytherapy places temporary tubes or catheters into the prostate. A radioactive source travels through them for a short period and is then removed.

Neither is universally better. The appropriate approach depends on cancer risk, prostate anatomy, urinary function, treatment goals and whether external radiation is also planned.

Yes. Selected men with localized low-risk prostate cancer can receive brachytherapy as definitive treatment. Active surveillance is another option for some patients.

Yes. It can be used alone in selected cases or combined with external beam radiation and sometimes hormone therapy.

Yes, in selected patients. High-risk disease may receive external beam radiation with a brachytherapy boost and hormone therapy.

For appropriately selected localized prostate cancer, brachytherapy can be used with curative intent.

The implantation procedure is generally performed under anaesthesia. Some soreness, bruising or urinary discomfort can occur afterward.

Yes. Frequency, urgency, burning, weak urine flow and difficulty emptying the bladder can occur.

Yes, particularly in patients who already have significant urinary obstruction or certain prostate characteristics.

It can. Erectile function may decline gradually after treatment, and the risk depends on several patient and treatment factors.

It can affect semen volume and ejaculation. The effect may be different from radical prostatectomy because the prostate remains in place.

Fertility can be affected by prostate radiation. Men who may want biological children should discuss fertility preservation before treatment.

The radiation from permanent seeds is low and decreases over time, but temporary precautions may be recommended, particularly around pregnant women and young children. Follow the instructions given by the treating team.

Yes, but patients should follow their hospital's radiation-safety instructions and carry treatment documentation because security systems at airports may detect implanted radioactive material.

Because the radioactive source is removed, there is no permanent radioactive source left in the prostate. Travel timing still depends on recovery from the procedure and anaesthesia.

LDR commonly involves one implantation procedure. HDR can involve one or more treatment sessions depending on the treatment plan.

Many patients have a short stay. HDR brachytherapy may require one or two days depending on the protocol.

Yes. This is commonly considered for selected higher-risk disease.

Yes. Hormone therapy may be used with radiation for higher-risk disease or before treatment to shrink a large prostate.

They are different treatment approaches. The appropriate choice depends on the cancer, patient health, urinary function, treatment goals and potential side effects.

The costs vary by hospital and treatment plan. Published estimates for brachytherapy can be lower than many robotic prostatectomy quotations, but the comparison must include all treatment components.

Apollo Hospitals currently publishes a general brachytherapy estimate of approximately ₹1 lakh–₹2.5 lakh. GAF Healthcare planning ranges for brachytherapy in India are $5,500–$13,000. The actual cost depends on the technique, hospital, treatment plan and additional therapies.

Yes. Specialised cancer centres in India offer prostate brachytherapy, including LDR and/or HDR depending on the centre.

Send the PSA history, biopsy and pathology report, Gleason score, Grade Group, MRI reports, PSMA PET/CT where available, previous treatment records and medication list.

The treatment depends on whether the recurrence is local or distant. Options may include hormone therapy, systemic treatment and selected salvage procedures.

Brachytherapy is a targeted form of internal radiation therapy that can treat selected prostate cancers without removing the prostate.

There are two main types:

LDR brachytherapy — permanent radioactive seeds, radiation delivered gradually, often used alone for selected localized disease.

HDR brachytherapy — temporary catheters, short high-dose radiation delivery, often used as a boost with external beam radiation.

Brachytherapy can be particularly useful when the treatment team wants to deliver a high dose directly to the prostate.

However, it is not suitable for everyone.

The most important factors include cancer stage, Grade Group, PSA, risk group, prostate size, urinary function, previous prostate procedures and overall health.

The major side effects involve urinary irritation, urinary frequency, difficulty passing urine, bowel irritation and erectile dysfunction.

For LDR treatment, temporary radiation-safety precautions may be necessary because the seeds remain inside the prostate.

For HDR treatment, the radioactive source is removed after treatment.

In India, published general brachytherapy costs are approximately ₹1 lakh–₹2.5 lakh, while GAF planning ranges are $5,500–$13,000. Patients should obtain a prostate-specific, itemised quotation from the treating centre.

For international patients, the complete budget should include diagnosis, treatment, hospitalisation, accommodation, travel, follow-up and any additional radiation or hormone therapy.

This article stays focused on brachytherapy and connects to:

GAF Healthcare coordinates international patients who want brachytherapy for prostate cancer in India. Share PSA reports, biopsy and Grade Group, MRI or PSMA PET, urinary-symptom details and previous TURP records. A coordinator can arrange review with a radiation oncologist, confirm whether the centre offers LDR, HDR or both, and prepare an itemized estimate. The treating radiation oncology team makes the final recommendation.

This article is for general educational purposes and does not replace medical advice from a qualified radiation oncologist, urologist or multidisciplinary prostate cancer team.

The suitability of LDR or HDR brachytherapy depends on the individual's PSA, Grade Group, stage, prostate anatomy, urinary function, previous procedures and overall health.

Treatment outcomes, side effects, treatment schedules and costs vary between patients and hospitals. Published prices are indicative and can change. Patients should obtain a current treatment plan and written quotation from the treating hospital before making medical or travel arrangements.

1. American Cancer Society — Radiation Therapy for Prostate Cancer — LDR and HDR brachytherapy, eligibility, procedure, radiation precautions and side effects.

2. European Association of Urology — Radiotherapy for Prostate Cancer — patient-focused radiotherapy, combination treatment and side effects.

3. Prostate Cancer UK — High-Dose-Rate Brachytherapy — HDR eligibility, preparation, procedure, recovery and combination treatment.

4. Prostate Cancer UK — Permanent Seed Brachytherapy — LDR seed implantation, how the seeds work and treatment duration.

5. Apollo Hospitals — Brachytherapy — India-specific information, potential complications and an indicative published cost range.

Last reviewed against the cited sources: September 2026.